Evaluation of the Effects of TAK‑242 and GIT‑27 on Methotrexate‑Induced Liver Injury

Abstract

Background: Methotrexate (MTX)‑induced liver injury is a common problem that is described as increased level of hepatic biomarkers thatis seen in 14%–25% of patients with inflammatory bowel disease and 49% of patients with rheumatoid arthritis or as idiosyncratic inducedliver injury that is seen in 1% of patients with inflammatory bowel disease, or as fibrosis and cirrhosis in 17% of rheumatoid arthritis patients and 25% of psoriatic patients. This profile may rarely progress to acute liver failure. Aim: The aim is to study the effect of TAK‑242 and GIT‑27 on MTX‑induced liver injury. Materials and Methods: Thirty‑five Albino‑Wistar rats were divided into five groups: the first group was maintained on distilled water, the second group was administered intraperitoneal (I.P.) dimethyl sulfoxide followed by oral MTX, the third group was administered oral MTX, the fourth group was administered I.P. TAK‑242 followed by oral MTX, and the fifth group wasadministered I.P. GIT‑27 followed by oral MTX. Results: The significant increase in markers of hepatic function, inflammatory and oxidativestress markers, as well as severe liver histopathologic change “steatosis” induced by methotrexate were alleviated in the animals pretreated with the drugs TAK-242 and GIT-27. With significant improvement in serum level of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, interleukin-6, tumor necrosis factor-α, malondialdehyde and reduced glutathione; beside an improved histopathologic profile of moderate steatosis. Conclusion: This study suggests that both TAK‑242 and GIT‑27 protect against liver injury induced by MTX depending on their antagonism of the inflammatory Toll‑like receptors 4 and 2/6.